LETTERS



Published by the American Association for the Advance ment of Science (AAAS), Science serves its readers as a forum for the presentation and discussion of important is sues related to the advancement of science, including the presentation of minority or conflicting points of view, rather than by publishing only material on which a consensus has been reached. Accordingly, all articles published in Sci-ence-including editorials, news and comment, and book eviews—are signed and reflect the individual views of the authors and not official points of view adopted by the AAAS or the institutions with which the authors are affi

The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.

Membership/Circulation

Director: Michael Spinella

Deputy Director: Marlene Zendell Member Services: Rebecca Dickerson, Manager; Mary Curry, Supervisor; Pat Butler, Helen Williams, Laurie Rako Representatives

Marketing: Dee Valencia, Manager; Jane Pennington, Europe Manager; Hilary Baar, Associate; Angela Mumeka, Coordinator Research: Renuka Chander, Manage Business and Finance: Robert Smariga, Manager; Kevin Bullock, Nina Araujo de Kobes, Coordinators Computer Specialist: Chris Hageman Science Member Services Danbury, CT: 800-731-4939 Washington, DC: 202-326-6417

Other AAAS Programs: 202-326-6400

Advertising and Finance

Associate Publisher: Beth Rosner

Advertising Sales Manager: Susan A. Meredith Recruitment Advertising Manager: Janis Crowley Business Manager: Deborah Rivera-Wienhold Finance: Randy Yi, Senior Analyst; Shawn Williams, Analy

Marketing: John Meyers, Manager; Allison Pritchard, Associat

Traffic: Carol Maddox, Manager; Christine Pierpoint, Associate

Recruitment: Terri Seiter Azie, Assistant Manager; Pamela Sams, Production Associate; Celeste Miller, Bethany Ritchey, Rachael Wilson, Sales; Debbie Cummings, *European Sales* Reprints: Corrine Harris

Permissions: Lincoln Richman

Exhibits Coordinator: Arlene Ennis PRODUCT ADVERTISING SALES: East Coast/E.

Canada: Richard Teeling, 201-904-9774, FAX 201-904-9701 • Midwest/Southeast: Elizabeth Mosko, 312-665-1150, FAX 312-665-2129 • West Coast/W. Canada: Neil Boylan, 415-673-9265, FAX 415-673-9267 • UK, Scandinavia, France, Italy, Belgium, Netherlands: Andrew Davies, (44) 1-457-838-519, FAX (44) 1-457-838-898 · Germany/Switzerland/Austria: Tracey Peers, (44) 1-270-760-108, FAX (44) 1-270-759-597 • Japan: Mashy Yoshikawa, (3) 3235-5961, FAX (3) 3235-5852 **RECRUITMENT ADVERTISING SALES: US: 202-326** 6555, FAX 202-682-0816 • Europe: Debbie Cummings, +44 (0) 1223-302067, FAX +44 (0) 1223-576208 • Australia/New Zealand: Keith Sandell, (61) 02-922-2977, FAX (61) 02-922-1100

Send materials to Science Advertising, 1333 H Street. NW, Washington, DC 20005.

Information for Contributors appears on pages 112–114 of the 6 January 1995 issue. Editorial correspondence, including requests for permission to reprint and reprint orders, should be sent to 1333 H Street, NW, Washington, DC 20005. Science World Wide Web address: http://www.aaas.org Other Internet addresses: science_editors@aaas.org (for general editorial queries); science_letters@aaas.org (for letters to the editor); science_reviews@aaas.org (for returning manuscript reviews); membership@aaas.org (for mem-ber services); science_classifieds@aaas.org (for submitting classified advertisements); science_advertising@aaas.org (for product advertising)



Serious concerns

Correspondents focus on test animals in a continuing discussion of how to assess risks from the many substances that must be tested for possible toxic effects to humans; an advocate of Lyme disease patient groups points to "mounting" evidence that the Lyme disease spirochete, Borrelia burgdorferi (above), can persist in some patients despite antibiotic treatment; and a representative of the American Academy of Actuaries speaks out on genetic discrimination.

Lyme Disease Research

The main focus of Eliot Marshall's article "Lyme disease: NIH gears up to test a hotly disputed theory" (News & Comment, 13 Oct., p. 228) is the controversy between patient advocacy groups and treating physicians on one side, and university-based researchers (who frequently dispute the existence of chronic Lyme disease) on the other. The article reports that the patient groups' tactics to have chronic Lyme disease studied "have angered research leaders such as Allen Steere of Tufts University." Is patient-initiated research really so bad?

Steere has been one of the most outspoken skeptics about the existence of a chronic Lyme disease epidemic (1) and one of the most outspoken proponents of the success of modest (10- to 30-day) courses of antibiotics (1). In 1993, Steere wrote (2) that, in Lyme disease, "Standard antibiotic treatment probably fails less often than one might think. Most apparent treatment failures actually reflect misdiagnosis."

However, evidence is mounting that the Lyme disease spirochete, Borrelia burgdorferi, can persist in some patients despite antibiotic therapy. The spirochete has been isolated from the skin (3, 4), spinal fluid (4, 4)5), blood (6), ligamentious tissue (7), and iris tissue (8) of patients after antibiotic therapy, including intravenous or long courses of supposedly curative antibiotics, or both (9).

It may surprise some to learn that in the first few years he was associated with Lyme disease, Steere promoted the idea that antibiotics were ineffective. In 1977 (10), Steere and his colleagues stated, "We remain skeptical that antibiotic therapy helps." In 1978, Steere and his colleagues wrote (11), "To sum up the therapy of Lyme arthritis (Lyme disease), it appears that at this point only symptomatic treatment is feasible." In a 1979 paper about the neurological abnormalities of Lyme disease (12), Steere and his colleagues reported that they "have noted no benefit from antibiotic treatment." However, an extensive literature search revealed 17 medical papers published before 1979 reporting the efficacy of antibiotics in treating Lyme disease. Only one (besides Steere's) reported no benefit.

The controlled studies (12) to see whether longer term antibiotics can help prevent chronic or relapsing Lyme disease (both successful) were performed in Europe. As Steere himself is quoted by Marshall as saying, the proposed National Institutes of Health study of chronic Lyme disease "would never have been funded" through the "normal mechanisms" of investigatorinitiated research.

Peter McFadden

4611 Governor's Drive, Huntsville, AL 35805, USA

References

- 1. A. C. Steere et al., J. Am. Med. Assoc. 269, 1812 (1993).
- _, *Hosp. Prac*. (April 1993), p. 37.
- 3. D. Hassler et al., Lancet 338, 193 (1991).
- 4. V. Preac-Mursic et al., Infection 17, 355 (1989). 5. H. Pfister et al., J. Infect. Disease 163, 311 (1991).
- 6. E. Masters et al., "Spirochetemia two weeks post cessation of six months of continuous p.o. Amoxicillin therapy" (Abstr. 65. Fifth International Conference on Lyme Borreliosis, Arlington, VA, 1992).
- 7. T. Haupl et al., Arthritis Rheum. 36, 1621 (1993).
- 8. V. Preac-Mursic et al., J. Neuro-ophthalmol. 13, 155 (1993)
- 9. P. Wahlberg et al., J. Infect. 29, 255 (1994); I. Bojic et al., Glas. Srp. Akad. Nauka Umet Od. Med. Nauka 43, 257 (1993).
- 10. A. C. Steere et al., Ann. Intern. Med. 86, 685 (1977)
- 11. A.C. Steere et al., Hosp. Pract. (April 1978), p. 143
- 12. L. Reik and A. C. Steere, Medicine 58, 281 (1979).

Diet and Test Animals

Philip H. Abelson's editorial "Flaws in risk assessments," (13 Oct., p. 215) correctly points out the critical role that diet can play

SCIENCE • VOL. 270 • 1 DECEMBER 1995